ACAD Acadia Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ACAD

Price (delayed)

$20.84

Market cap

$3.41B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.69

Enterprise value

$3.35B

Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who ...

Highlights
The net income is up by 46% year-on-year and by 24% since the previous quarter
The EPS has increased by 46% YoY and by 24% QoQ
The quick ratio has declined by 43% year-on-year but it is up by 16% since the previous quarter
The company's equity fell by 9% YoY but it rose by 6% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.acadia-pharm.com
Peers: VNDA PFE JNJ LLY

Key stats

What are the main financial stats of ACAD
Market
Shares outstanding
163.73M
Market cap
$3.41B
Enterprise value
$3.35B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.56
Price to sales (P/S)
6.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.07
Earnings
Revenue
$550.9M
EBIT
-$105.9M
EBITDA
-$102.71M
Free cash flow
-$34.31M
Per share
EPS
-$0.69
Free cash flow per share
-$0.21
Book value per share
$2.43
Revenue per share
$3.37
TBVPS
$3.51
Balance sheet
Total assets
$642.77M
Total liabilities
$246.98M
Debt
$49.78M
Equity
$395.79M
Working capital
$304.69M
Liquidity
Debt to equity
0.13
Current ratio
2.62
Quick ratio
2.49
Net debt/EBITDA
0.65
Margins
EBITDA margin
-18.6%
Gross margin
97.5%
Net margin
-20.1%
Operating margin
-23.1%
Efficiency
Return on assets
-17.8%
Return on equity
-27.8%
Return on invested capital
-35%
Return on capital employed
-23.3%
Return on sales
-19.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACAD stock price

How has the Acadia Pharmaceuticals stock price performed over time
Intraday
-3.2%
1 week
-11.54%
1 month
-23.07%
1 year
29.12%
YTD
30.9%
QTD
-12.99%

Financial performance

How have Acadia Pharmaceuticals's revenue and profit performed over time
Revenue
$550.9M
Gross profit
$537.23M
Operating income
-$127.48M
Net income
-$110.82M
Gross margin
97.5%
Net margin
-20.1%
The net margin has increased by 50% YoY and by 28% QoQ
The net income is up by 46% year-on-year and by 24% since the previous quarter
The operating margin has increased by 43% YoY and by 27% QoQ
The operating income has grown by 38% YoY and by 22% from the previous quarter

Growth

What is Acadia Pharmaceuticals's growth rate over time

Valuation

What is Acadia Pharmaceuticals stock price valuation
P/E
N/A
P/B
8.56
P/S
6.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.07
The EPS has increased by 46% YoY and by 24% QoQ
ACAD's price to book (P/B) is 11% higher than its last 4 quarters average of 7.7
The company's equity fell by 9% YoY but it rose by 6% QoQ
ACAD's P/S is 45% below its 5-year quarterly average of 11.3 but 7% above its last 4 quarters average of 5.8
ACAD's revenue is up by 8% YoY and by 6% QoQ

Efficiency

How efficient is Acadia Pharmaceuticals business performance
The ROS has soared by 52% YoY and by 31% QoQ
Acadia Pharmaceuticals's return on assets has increased by 42% YoY and by 25% QoQ
The ROE has grown by 33% YoY and by 22% from the previous quarter
ACAD's return on invested capital is up by 22% since the previous quarter and by 21% year-on-year

Dividends

What is ACAD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACAD.

Financial health

How did Acadia Pharmaceuticals financials performed over time
The total assets is 160% more than the total liabilities
The quick ratio has declined by 43% year-on-year but it is up by 16% since the previous quarter
The current ratio has contracted by 42% YoY but it has grown by 17% from the previous quarter
The debt is 87% lower than the equity
The debt has decreased by 9% YoY and by 3.2% QoQ
The company's equity fell by 9% YoY but it rose by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.